A number of drugs can cause precipitates within renal tubules leading to crystal nephropathy. Crystal nephropathy is usually an exposure-related finding and is not uncommon in preclinical studies, where high doses are tested. An understanding of the nature of precipitates is important for human risk assessment and further development. Our aim was to investigate the ability of various imaging techniques to detect the presence of drugs or metabolites in renal crystals. We applied matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR MS) imaging, Raman and infrared microspectroscopy, scanning electron microscopy coupled with energy dispersive X-ray (SEM/EDX) spectroscopy and standard histopathology to cases of drug-induced crystal nephropathy, induced in rodents and primates by 4 compounds. MALDI-FTICR MS imaging enabled the identification of the drug-related crystal content in all 4 cases of nephropathy, without reference material and with high accuracy. Crystals were composed of unchanged parent drug and/or metabolites. Similar results were obtained using Raman and infrared microspectroscopy for 2 compounds. In the absence of reference standards of metabolites, Raman and infrared microspectroscopy showed that the crystals consisted of components similar, but not identical, to the administered drug for the other compounds, a limitation for these techniques. SEM/EDX showed which counter ions were colocalized with the identified drug-related material, complementing the MALDI-FTICR MS findings. Therefore, we recommend MALDI-FTICR MS as a first-line methodology to characterize crystal nephropathies. Raman and infrared microspectroscopy may be useful when MALDI-FTICR MS imaging cannot be applied. SEM/EDX could be considered as a complementary technology.
function (Nasr et al., 2014) and precipitates are primarily due to oversaturation of urine or drug insolubility at alkaline or acidic urine pH (Yarlagadda and Perazella, 2008) . Recent investigations suggest that innate immunity mechanisms might also contribute to the kidney injury associated with crystal deposits (Mulay et al., 2014) .
Crystal nephropathy is usually an exposure-related finding and is not uncommon in preclinical studies, where high doses of compounds are tested. The potential of a drug or its metabolites for precipitation in renal tubules is a concern, in particular for patients with renal impairment. Often crystal nephropathy can only be confirmed by examination of unstained frozen sections under polarized light. The identification of crystals and a good understanding of the nature of precipitates are therefore important for human risk assessment and further development of a drug candidate.
A variety of imaging techniques to determine the presence of drugs or metabolites in tissue sections are now available and are being utilized more extensively in preclinical safety studies. Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) imaging is an in situ technique for generating mass spectra that allows for simultaneous analysis of many molecules in the same tissue section. The typical experimental procedure involves target tissue isolation, preparation of tissue sections, spraying of a matrix onto the tissue surface followed by MS data acquisition. Ions, generated in the MALDI source by irradiating the matrix-coated tissue surface with an ultraviolet (UV) laser, are separated in a high-resolution mass spectrometer for acquisition of MS spectra. Data analysis includes identification of drug-related MS signals specific to the region of interest and extraction of relevant ion maps yielding reconstructed images.
In the past few years, significant progress has been achieved, both in instrument hardware and software, as well as in sample preparation procedures. This has led to major improvements in the speed, sensitivity, and spatial resolution of MS imaging technologies; the application of high mass-resolving analyzers, such as the Fourier transform ion cyclotron (FTICR), have particularly contributed to this progress (Prideaux and Stoeckli, 2012) . Caprioli and coworkers were the first to employ MALDI-FTICR to visualize the presence of olanzapine and its 2 metabolites in rat liver and kidney (Cornett et al., 2008) . Since then, MALDI-FTICR imaging has become increasingly popular in the pharmaceutical industry for the identification and localization of drugs and metabolites in tissues. Recently, MALDI imaging even from archived tissue samples has become more feasible, because appropriate protocols are now available (Bruinen et al., 2016; Ly et al., 2016) .
A combination of classical histopathologic techniques with MALDI MS imaging can provide insights into whether drugs or drug metabolites are colocalized with lesions observed by histopathologic methods. By overlaying microscopic pictures, the spatial distribution of diverse analytes can be visualized in relation to the tissues and colocalized with histopathologic findings. As a visualization technique, MS imaging therefore provides a valuable addition to the histopathologist's toolbox, with the potential to support the characterization of toxicological observations and the interpretation of their relevance for humans.
Over the last decade vibrational spectroscopy techniques, ie, Raman and infrared (IR) imaging techniques, have also gained in popularity in the field of biomedical analyses and are receiving more attention in pathology (Smith et al., 2012) . Many applications in medical diagnostics and cellular biology benefit greatly from the high spatial resolution and absence of the need for sample preparation, thereby enabling the sample to be analyzed unaltered. In terms of tissue assessment, Raman microspectroscopy is being developed as a diagnostic tool in tissue section evaluation, whereby the focus has been on changes in biochemical composition of tissues (Diem et al., 2012; Huser and Chan, 2015; Kong et al., 2015) , for example to detect neoplastic cells prior to and during surgery. Raman and IR microspectroscopy have been applied to identify the composition of crystals in tissue sections (Siam et al., 2007; Thompson et al., 2008) .
We recently observed, in preclinical toxicity studies, findings suggestive of drug-induced crystal nephropathy with multiple molecules that possess various chemical structures and pharmacological activities. To characterize the composition of the crystals we applied the aforementioned imaging techniques, combined with scanning electron microscopy coupled with energy dispersive X-ray (SEM/EDX) spectroscopy, to cases of druginduced crystal nephropathies in rodents and/or primates. Here, we present the outcome of these investigations, compare the different techniques, and propose a tiered approach for characterization of crystal nephropathies.
MATERIALS AND METHODS
Samples. Kidney samples were obtained from 7 toxicity studies in the rat, mouse or cynomolgus monkey in which renal findings suggestive of crystal nephropathy had been observed. Four different compounds (RO5372709, RO4917523 (Jaeschke et al., 2015) , RO6809959, and RO0728617 (Flohr et al., 2003) ) with various chemical structures and pharmacological activities were tested in these studies (Table 1 ). All 4 compounds are proprietary Roche drug candidates for the treatment of neurological and psychiatric diseases. RO5372709 and RO4917523 are metabotropic glutamate receptor 5 negative allosteric modulators and RO0728617 is a ligand of the A 2a receptor. For RO6809959 the target is unknown. Previously, renal findings were observed in pivotal toxicity studies during the pharmaceutical development of these compounds. These findings were observed at different time points during development of these compounds. Therefore, the examined samples were derived from studies of different duration (varying from 1 to 26 weeks), and not all compounds were tested in all species.
All studies were performed in a laboratory approved by the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) or the Swiss Federal Act on Animal Protection (Swiss APA 1978) in accordance with Swiss Animal Protection law.
Microscopic examination
Histopathologic examination was performed on hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) stained paraffin sections of the kidneys. To confirm the presence of crystals or for the examination for presence of crystals 10 lm thick frozen sections from the kidneys of selected control and treated animals were mounted on glass slides without further staining and examined microscopically. Kidney samples with crystal deposits, as well as kidneys of animals without crystal deposits, were selected for imaging investigations as outlined in Table 1 .
Raman microspectroscopy
Frozen kidney sections 10 lm thick were mounted on glass slides and examined without further staining. Raman microspectroscopy was performed with a Horiba Jobin Yvon ARAMIS Raman microscope based on an Olympus BX41 microscope equipped with a Peltier cooled charge coupled device (CCD) detector. Spectra were measured with laser excitation of 633 nm, 600 l/mm grating, using a Â50 or Â100 objective and 3-5 exposures of at least 5 s. For the Raman measurements, areas with high birefringence under cross polarizers, consistent with crystalline material, were compared with areas without birefringence chosen as background spectra compensation. Additionally, for molecules with a triple bond in their structure, the birefringent areas were checked for a Raman band in the range 1900-2600 cm
À1
, which can be attributed to a carbon-carbon (C-C) triple bond. The measured spectra were compared with Raman spectra of reference compounds, ie, the parent compounds (free base or salt), or available metabolites.
Some of the initial experiments were repeated with a Horiba Jobin LabRam EVO Raman microscope with similar experimental set-up as the Aramis Raman microscope.
Infrared microspectroscopy
Unstained frozen sections of the kidney 10 mm thick mounted on barium fluoride (BaF 2 ) slides were analyzed. IR spectra were recorded in the range of 900-3900 cm À1 using a Hyperion 3000 (Bruker, Bremen, Germany) equipped with a mercury cadmium telluride (MCT) detector, focal plane array (FPA) detector and polarizers in the visualization beam. Spots samples with high birefringence (crystalline material) and without birefringence were selected for analysis. The spectra were measured in transmission either with the MCT single area detector, or as a 270 Â 270 lm 2 area using the FPA detector with a spectral resolution of 4 cm À1 and a spatial resolution of 10 lm (32 Â 32 pixels; 2 Â 2 pixel binning). For transmission with the MCT single area detector, the measurement area was restricted to the crystalcontaining area. The measured spectra were compared with IR spectra of reference compounds, parent compounds (free base or salts), or available metabolites. Reference spectra were either measured at the microscope (parameters as above) or by transmission Fourier transform infrared (FTIR) measurements in Nujol oil (mineral oil) suspensions.
MALDI-FTICR mass spectrometry imaging
Kidney sections of animals showing crystal nephropathy under light-microscopic examination were investigated. Frozen kidney tissue was cut into 10 lm thick sections using a cryomicrotome (Leica, Germany) and thaw mounted on Superfrost microscope glass slides (Thermo Scientific, Germany). Unstained slides were dried in a vacuum desiccator at room temperature for at least 45 min before being microscopically examined for crystalline deposits under polarized light. Finally, the slides were scanned with an Aperio ScanScope slide scanner (ScanSope AT) and submitted to MALDI-FTICR MS analysis. Prior to MALDI-FTICR MS analysis, a solution of a-cyano-4-hydroxycinnamic acid (CHCA) at 10 mg/ml in 1:1 acetonitrile (ACN):0.1% 2,2,2-trifluoroethanoic acid (TFA) in water was applied for coating the tissue slices using an iMatrixSpray sprayer (Stoeckli et al., 2014) . Four spraying cycles were applied at a flow rate of 5 ml/cm 2 . The tissue samples were analyzed on a 7 Tesla SolariX XR FTICR MS instrument with a MALDI source equipped with a smart beam laser II laser (Bruker Bremen, Germany). Ions were detected in positive ionization mode over a mass range of m/z 150-3000 with a lateral resolution of 50 mm. Two hundred laser shots using sequential settings were applied per pixel at 2000 Hz, setting laser power to 20%. The signal for each pixel was normalized against the root mean square (RMS) of all data points. This normalization method divides all spectra by the RMS of all data points, and works well when all spectra in the dataset are expected to have similar peak intensities. Ion images were coregistered with an optical scan generated from the tissue slice before MS imaging using an optical scanner (OpticLab H850, Plustek, Germany). All MS images were generated with FlexImaging 4.0 software (Bruker, Bremen Germany).
Compounds and metabolites were identified either by comparison of the observed MS versus the MS spectra of standard compounds or by matching to accurate mass calculated based on elemental formulae.
SEM/EDX analysis
Frozen kidney sections from 4 studies were mounted on the SEM holder using a conductive, adhesive tape. Crystal-rich areas were identified. SEM/EDX measurements were performed on crystal-rich and crystal-free areas with a Quanta FEG250, FEI, equipped with EDX detector Apollo XL (EDAX). SEM/EDX measurement spots were chosen by the presence of fluorine (F), to ascertain that the composition of the crystal was related to the test molecule or its metabolite. The presence of the elements fluorine (F), chlorine (Cl), sodium (Na), magnesium (Mg), and calcium (Ca) was checked and measured by EDX.
RESULTS

Microscopic Examination
Nephropathy was observed in the rat, mouse, and cynomolgus monkeys, and the findings are summarized in Table 2 . Histological features of crystal nephropathy were similar for RO5372709, RO4917523, and RO6809959. They consisted of focal/ multifocal to locally extensive tubular degeneration/regeneration (mainly positioned around distal tubular segments) and occasional tubular cell necrosis, which were accompanied by tubular dilation and casts. Affected areas partially extended in a striped/ band-like distribution from the outer cortex to the papilla (shown for RO5372709 [Figs. 1A and B] and RO49175232 [Figs. 1C and D] ). Inflammation of various degrees was present and ranged from (Figure 2 ). Crystals were seen intratubularly or, for RO0728617, interstitially. The crystalline structures were birefringent with polarized light. Tubular deposits were mainly seen in distal tubules. The crystals were considered the cause of the nephropathy.
MALDI-FTICR Mass Spectrometry Imaging
The 4 drug candidates were investigated further by MALDI-FTICR MS imaging in order to determine whether the crystals were composed of the parent drug compound, metabolites, or an endogenous compound formed as a reaction to the drug administration. In Figure 2 , crystal deposits in kidney tissue sections of all 4 compounds (A, D, G, and J) are displayed together with an overlay of their respective MALDI-FTICR MS images with an optical scan (B, E, H, and K) to visualize the spatial distributions of the displayed analytes (C, F, I, showing the metabolic transformation, and L showing the parent compound). Mass signals colocalized with the crystals were observed for all 4 compounds; for RO0728617 the unchanged parent drug was detected, for the 3 other compounds, the crystals consisted of acidic metabolites, with no or little parent drug being observed as described below. Investigation of rat kidney tissue slices of RO5372709 by MALDI MS imaging revealed an association of crystals with a signal of m/z 335.11387, with a mass accuracy of < 1 ppm (Figs. 1A-C) . This corresponds to the protonated form of a metabolite formed by oxidation of RO5372709 to a carboxylic acid. When the molecular distribution was overlaid with the optical image of the tissue section (Figs. 1A-C) , the spatial distribution of this metabolite clearly coincided with the presence of kidney crystals found during histopathologic investigation. For RO4917523, a structural analog of RO5372709, investigation of cynomolgus monkey kidney tissue slices by MALDI MS imaging revealed an association of crystals with a signal of m/z 556.06834, corresponding to the potassium adduct of a hydroxylated and glucuronidated metabolite, with a mass accuracy of < 1 ppm (Figs. 1D-F) . Additionally, in rat and mouse kidney tissue sections, this metabolite was found to be colocated with the detected crystals. For RO6809959, MALDI MS imaging of crystals in cynomolgus monkey kidney tissue slices lead to identification of m/z 322.05898, the protonated form of a metabolite formed by oxidation of RO6809959 to a carboxylic acid, with a mass accuracy of < 1 ppm (Figs. 2G-I ). For RO0728617, the crystals identified in rat kidney sections corresponded to the protonated form of the parent compound at a signal of m/z 454.1907, with a mass accuracy of < 1 ppm (Figs. 2J-L).
Raman Microspectroscopy
Raman spectra were collected from all kidney slides examined. Different types of spectra were recorded for birefringent spots and background (non-birefringent tissue). Raman spectra measured from the crystals were identical or similar to spectra of the parent compound or their metabolites (Figure 3 ), indicating that those chemical entities were responsible for the crystal formation.
For RO5372709, a Raman band for the C-C triple bond at approximately 2220 cm À1 , which is a characteristic band for this molecule, was found within crystals displaying high birefringence. The Raman spectra were identical to a metabolite of this compound. For RO4917523, a C-C triple bond signal at 2220 cm À1 , typical for this molecule, was seen within the crystals in all species examined, indicating the same chemical entity was responsible for the crystal formation in the different species. However, no complete match with known reference spectra was found. For RO6809959, all crystalline areas displayed similar Raman spectra. The spectra were similar but not identical to the parent molecule or the main metabolite. From the spectra it was deduced that the chemical structure must bear some similarities to both the parent compound and metabolite, suggesting that the crystals may consist of a different metabolite. For RO0728617, Raman spectra of crystalline areas matched with the Raman spectra of the parent compound as hydrochloride salt, and were different to the parent compound as free base. The findings of the Raman microspectroscopy are summarized in Table 3 .
Infrared Microspectroscopy
IR transmission spectra were collected from the crystals (Figure 3 ). For RO5372709, a band for the stretching vibration of the carboxyl (-COOH) group was found at $1700 cm À1 in the sample spectra; it was similar to the spectra obtained from a metabolite with a carboxyl group. The spectra were clearly distinguishable from IR spectra of the parent compound, and from the alcohol. The intensity in the stretching vibrations of -COOH correlated with the appearance of crystals as seen with polarized light with all FTIR FPA measurements. Therefore, the crystals were considered to be consistent with the major metabolite. . RO6809959 E and F, Tubular degeneration/regeneration in a high-dose male monkey from the 2-week study (E). Tubulo-interstitial inflammation with multinucleated giant cells (arrows) and crystal clefts from the same animal at the higher magnification) (F). RO0728617 G and H,
Stripes of tubular degeneration/regeneration (arrows) in a high-dose female rat from the 4-week study (G). At a higher magnification tubular degeneration/regeneration and crystal clefts (arrows) in the interstitium (H).
No perfect match was found for the reference spectra for RO4917523, including the parent compound free base and chloride salt, or M1, M1 glucuronide, and M2. With the FTIR spectrum of the M1 glucuronide, the sample spectrum shared the following features: bands indicating the presence of -OH groups (in the region above 3300 cm showed additional bands at 1045 and 985 cm À1 . In the carbonyl stretching region the band at 1738 cm À1 was missing, and at 1674 cm À1 only a very weak band could be found in the sample spectrum. In the fingerprint region, the band at 1141 cm À1 was missing. These findings pointed to a composition similar to M1 glucuronide, yet not identical. It was considered especially unlikely that the carboxyl group was present in aqueous conditions with a low pKa. Either the carboxyl group was deprotonated and a salt was formed, or decarboxylation or reduction had taken place. For RO0728617, in crystalline areas, typical peaks were detected at 1596, 1300, and 1260 cm À1 as well as a broad band around 2750 cm À1 . Features between 2700 and 2400 cm À1 are typical for amine hydrochlorides, indicating the hydrochloride of the parent compound was present. The findings of the IR microspectroscopy are summarized in Table 3 .
SEM/EDX Analysis
Interpretable data were obtained for compounds RO4917523 and RO0728617 only. For RO4917523, all crystal areas contained more sodium (Na) than could be detected in the tissue background, whereas values found for magnesium (Mg) and calcium (Ca) were not elevated in crystal areas, when compared with the tissue background. These results pointed to the presence of additional Na in the crystals, most probably as a non-stoichiometric sodium salt (Table 4) . For RO0728617, the elemental composition of the tissue background and the crystal areas did not significantly differ with regards to Na, phosphorous (P), or potassium (K) ( 
DISCUSSION
In this study, MALDI-FTICR MS imaging enabled unequivocal identification of crystals in all cases of drug-induced crystal nephropathy. Crystals were shown to be composed of parent compound or metabolites, confirming that the nephropathy was due to their precipitation. The nature of the crystals could be unequivocally identified by Raman or IR microspectroscopy only for 2 compounds, but these techniques also showed that RO0728617 was present as a hydrochloride salt. However, for the other 2 compounds, crystals were only shown to be similar but not identical to the parent compound.
Drug-induced crystal nephropathy is a well-known side effect in drug research. The diagnosis of crystal nephropathy is straightforward if crystals, crystal-like clefts or even a foreign body reaction are evident in histopathology. This was the case for 2 of the compounds in our investigations. However, for the other 2 compounds only the histologic features (tubular degeneration and regeneration accompanied by tubular dilation) and Abbreviations: Cl, chlorine; IR, infrared; MALDI-FTICR MS, Matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry; Na, sodium; N/A, not applicable; S, sulfur; SEM/EDX, scanning electron microscopy coupled with energy dispersive X-ray.
the distribution within the kidney suggested crystal deposition as the cause of the nephropathy. Here, the definitive proof was only evident after examination of unstained frozen kidney sections under polarized light. In the case of RO0728617, crystals were mainly found interstitially. The cause of this distribution
is not yet known, and is currently being investigated. Crystal nephropathy was seen in all species examined. However, rodents seemed to be most sensitive as findings occurred at lower exposures compared with cynomolgus monkeys. This is consistent with previous reports that show rodents are more susceptible to develop drug precipitation in the kidney tubules as they have a high urine concentrating capacity compared with other species (Khan and Alden, 2003) . The higher susceptibility of rodents to drug precipitation, however, does not preclude the risk of crystal nephropathy in humans. Therefore, identification and characterization of the crystals in preclinical species is of great importance. Depending on the nature of the crystals (ie, whether they consist of the parent compound or metabolites) and their potential species specificity, risk assessment may differ significantly. For example, metabolite-induced crystal nephropathy might not be relevant for humans if the metabolite is not formed or only formed in small quantities in clinical settings.
For risk assessment and translation of results from preclinical species to human, the human therapeutic dose is an important factor. Furthermore, the clearance pathways can significantly modulate renal exposure and local concentrations in kidney tissue. For example for RO4917523, even though the M1-glucuronide that crystallized in animal kidneys is also a major metabolite in human urine (Guerini et al., 2016) , the therapeutic dose in humans is several orders of magnitude lower compared with the doses administered in preclinical safety studies. Therefore it is unlikely that local concentrations of the compound in kidney tissue would reach levels comparable with those leading to crystal formation in animal safety studies. So far, no kidney injury has been observed in any of the clinical studies performed with this compound. In contrast, for RO5372709, even though no in vivo data are available due to discontinuation of its development, the in vitro metabolite pattern hints at significant differences in metabolic pathways between species. Although the acid metabolite detected in rat kidney crystals is the major metabolite in rat hepatocyte incubations, it is only minor in incubations with human hepatocytes. This illustrates how an understanding of the nature of precipitates in the context of species differences can be an important factor for human risk assessment, which potentially allows derisking of preclinical findings and further development of otherwise promising drug candidates.
The main advantage of MALDI-FTICR MS imaging is that it allows the accurate identification of material of unknown composition with high mass accuracy. In contrast Raman and IR microspectroscopy require the existence of the correct reference spectra of the analytes of interest, which can include also salts or polymorphs of the parent molecules and metabolites. Therefore, we recommend applying MALDI-FTICR MS imaging in the first instance when only the primary structure needs to be understood. We recommend considering Raman and IR microspectroscopy as second line technologies for cases where MALDI-FTICR MS imaging cannot be successfully applied, or if subcellular level information is needed. In addition, MALDI-FTICR MS imaging does not allow determination of the counter ion in case of precipitation of salts, but this information can be obtained by the microspectroscopy techniques, as shown in our investigations for RO0728617. Knowledge of the counter ion may be important for risk assessment in certain cases as some salts may raise more concern due to poor solubility and reduced probability of dissolution. In this situation, SEM/EDX spectroscopy can be used as a supplementary technique, as shown in our investigations for compounds 2 and 4. However, this technique will not distinguish between small ions present as a counterion of the analyte in question, or present due to another compound.
A key advantage of MALDI MS imaging is that mass spectra are obtained from tissue sections, allowing direct measurement of small molecules in tissues (Hsieh et al., 2006) . A broad spectrum of different analytes can now be determined in tissue specimens using this method (Aichler and Walch, 2015) . Proteins and protein modifications are ideally detected via MALDI-Time-of-Flight (TOF) whereas exogenous analytes as well as some endogenous analytes, such as lipids or hormones, are preferentially examined by high-resolution imaging MS such as MALDI-FTICR (Aichler and Walch, 2015) . In recent years there have been several reports of the application of MALDI MS imaging to detect drugs or metabolites in tissue sections in the context of preclinical toxicity and efficacy testing (BrignoleBaudouin et al., 2012; Buck and Walch, 2014; Castellino, 2012; Groseclose et al., 2015; Lagarrigue et al., 2016) . For instance, Nilsson et al. (2012) and Bruinen et al. (2016) characterized crystals in cases of crystal nephropathies in animals using MALDI-TOF, Abbreviations: Cl, chlorine; K, potassium; Na, sodium; P, phosphorous; S, sulfur.
whereas Groseclose et al. (2015) showed the presence of a drug metabolite in the regions of tubular deposits in the kidney by MALDI-FTICR MS imaging, but confirmed the deposits to be composed primarily of calcium phosphate. Raman and IR microspectroscopy are techniques based on detecting molecular vibrations, and provide complementary results based on the nature of the vibrations being probed (polarizable groups vs polar groups). In the pharmaceutical industry, Raman and IR microspectroscopy are well-established analytical techniques for release testing of raw materials, active pharmaceutical ingredients (APIs) and excipients. In addition, they are essential tools used for solid form understanding (polymorphism, solvation, and amorphous state), and in drug product development and manufacturing, as process analytical technology tools (Paudel et al., 2015) . This often results in the availability of a variety of reference spectra for one analyte. The techniques are also used in mapping applications for drug product formulations and for counterfeit detection (Gala and Chauhan, 2015) .
In the experiments presented here, the best results were achieved on unfixed, frozen tissues with all techniques, although Raman and IR microspectroscopy also work on fixed tissues. The embedding material might be critical, in particular for the MS response with MALDI-FTICR MS. Optimal cutting temperature polymers (OCT) are not favored, whereas agarose, gum or other polymers are suitable. Standard superfrost glass slides can be used for the MALDI-FTICR MS imaging analysis. For Raman microspectroscopy the best substrate is a quartz microscope slide, but it is also possible to use regular glass slides. For IR microspectroscopy, good substrates are zinc selenide (ZnSe) or BaF 2 microscope slides.
MALDI-FTICR MS can detect all kinds of analytes that produce ions in the MALDI source, up to approximately 10 kDa. Raman or IR signal can be retrieved from most analytes. One major drawback of Raman and IR microspectroscopy is that spectra cannot give conclusive structural confirmation without reference spectra. Hence, measured spectra need to be compared with known reference spectra of, for instance, parent API or metabolites. In addition, spectra will show differences with changes in solid state properties, such as polymorph or salt formation, of the molecule in question. In contrast, the identification of unknown analytes is possible with MALDI-FTICR MS as it allows a highly accurate identification of compounds with high mass accuracy, and further identification is possible via MS n experiments. Possible for all kinds of compounds that produce ions in the MALDI source 10 kDa.
All compounds containing elements from Boron will give an EDX signal.
Molecular identification
Requires reference spectra of analytes of interest.
Highly accurate identification of compounds with high mass accuracy, further identification possible via MS n experiments.
Identification of unknowns possible. Varies from 30 to 3 min per spectrum, depending on analyte.
Depends on the step size and scanned area. Easily in the range of hours. Data set is very large and computationally demanding.
$1 min.
Spatial resolution
<1 mm >20 mm >10 mm SEM: <1 mmEDX: $1 mm Abbreviations: IR, infrared; MALDI-FTICR MS, Matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry; OCT, optimal cutting temperature; ZnSe, zinc selenide; SEM, scanning electron microscopy; EDX: energy dispersive X-Ray.
Raman and IR microspectroscopy also have advantages over MALDI-FTICR MS imaging. Both techniques are non-destructive, whereas for MALDI-MS imaging the application of a matrix is required, and staining after measurement is possible only with limitations. In addition, Raman and IR microspectroscopy have quite short measurement times for individual spectra of crystals (seconds to minutes). In contrast, MALDI-MS imaging can take several hours, depending on the step size and scanned area, and the data output is large. Raman microspectroscopy also has the advantage that the spatial resolution is below 1 lm for certain laser wavelengths, whereas the current MALDI-MS images are in the 10 lm range. One additional advantage of Raman and IR spectroscopy is that they can detect the salt form of the analyte in question, whereas MALDI-FTICR MS imaging needs to be complemented by other techniques, such as SEM/ EDX spectroscopy. In addition, compared with Raman and IR spectroscopy MALDI imaging is still a resource intensive (quite expensive) technology with regard to instrument prices (taking into account acquisition costs) and costs for infrastructure and maintenance.
In conclusion, MALDI-FTICR MS imaging, Raman or IR microspectroscopy and SEM/EDX spectroscopy can be used to identify the compounds present in the renal crystals that are observed in crystal nephropathy. We recommend applying MALDI-FTICR MS imaging as a first line method for characterization of renal crystal deposits. Raman and IR microspectroscopy might be useful as second-line technologies for cases where MALDI-FTICR MS imaging cannot be successfully applied.
